Shares of Nuformix plc (LON:NFX – Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as GBX 0.18 ($0.00) and last traded at GBX 0.18 ($0.00), with a volume of 225 shares. The stock had previously closed at GBX 0.19 ($0.00).
Nuformix Stock Performance
The firm has a fifty day moving average of GBX 0.27 and a 200-day moving average of GBX 0.28. The stock has a market capitalization of £1.56 million, a price-to-earnings ratio of -1.63 and a beta of 0.38. The company has a quick ratio of 3.35, a current ratio of 1.51 and a debt-to-equity ratio of 1.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Value Stocks Too Small For Buffett’s Portfolio
- 5 discounted opportunities for dividend growth investors
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is Forex and How Does it Work?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
